Exelixis Inc Income (Loss) Attributable to Parent, before Tax
Exelixis Inc (EXEL) reported Income (Loss) Attributable to Parent, before Tax of $262.68 million for the 3-month period ending 2026-07-03, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:IncomeLossAttributableToParent · last filed 2026-08-05
- Exelixis Inc income (loss) attributable to parent, before tax for the quarter ending 2026-07-03 was $262.68M, a 14.00% increase year-over-year.
- Exelixis Inc income (loss) attributable to parent, before tax for the quarter ending 2026-04-03 was $267.69M, a 30.14% increase year-over-year.
- Exelixis Inc income (loss) attributable to parent, before tax for the quarter ending 2026-01-02 was $252.69M, a 36.76% increase year-over-year.
- Exelixis Inc income (loss) attributable to parent, before tax for the quarter ending 2025-10-03 was $252.41M, a 63.10% increase year-over-year.
- Exelixis Inc income (loss) attributable to parent, before tax for fiscal 2026 was $941.21M, a 38.08% increase from fiscal 2025.
- Exelixis Inc income (loss) attributable to parent, before tax for fiscal 2025 was $681.64M, a 164.69% increase from fiscal 2023.
- Exelixis Inc income (loss) attributable to parent, before tax for fiscal 2023 was $257.52M, a 9.89% increase from fiscal 2022.
- Exelixis Inc income (loss) attributable to parent, before tax for fiscal 2022 was $234.35M, a 20.33% decline from fiscal 2021.
| Period end | Income (Loss) Attributable to Parent, before Tax 3 month | Income (Loss) Attributable to Parent, before Tax 6 month | Income (Loss) Attributable to Parent, before Tax 9 month | Income (Loss) Attributable to Parent, before Tax 12 month |
|---|---|---|---|---|
| 2026-07-03 | $262.68M 10-Q · filed 2026-08-05 | $530.37M 10-Q · filed 2026-08-05 | $783.05M derived: sum of 3 quarters · filed 2026-08-05 | $1.04B derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-04-03 | $267.69M 10-Q · filed 2026-05-05 | $520.38M derived: sum of 2 quarters · filed 2026-05-05 | $772.79M derived: sum of 3 quarters · filed 2026-05-05 | $1.00B derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-01-02 | $252.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $505.10M derived: sum of 2 quarters · filed 2026-02-10 | $735.52M derived: sum of 3 quarters · filed 2026-08-05 | $941.21M 10-K · filed 2026-02-10 |
| 2025-10-03 | $252.41M 10-Q · filed 2025-11-04 | $482.83M derived: sum of 2 quarters · filed 2026-08-05 | $688.52M 10-Q · filed 2025-11-04 | $873.29M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-07-04 | $230.41M 10-Q · filed 2026-08-05 | $436.11M 10-Q · filed 2026-08-05 | $620.88M derived: sum of 3 quarters · filed 2026-08-05 | $775.63M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-04-04 | $205.69M 10-Q · filed 2026-05-05 | $390.46M derived: sum of 2 quarters · filed 2026-05-05 | $545.22M derived: sum of 3 quarters · filed 2026-05-05 | $838.06M derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-01-03 | $184.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $339.53M derived: sum of 2 quarters · filed 2026-02-10 | $632.37M derived: sum of 3 quarters · filed 2026-02-10 | $681.64M 10-K · filed 2026-02-10 |
| 2024-09-27 | $154.75M 10-Q · filed 2025-11-04 | $447.60M derived: sum of 2 quarters · filed 2025-11-04 | $496.87M 10-Q · filed 2025-11-04 | $599.91M derived: sum of 4 quarters · filed 2026-02-10 |
| 2024-06-28 | $292.85M 10-Q · filed 2025-07-28 | $342.11M 10-Q · filed 2025-07-28 | $445.15M derived: sum of 3 quarters · filed 2026-02-10 | $450.97M derived: sum of 4 quarters · filed 2026-02-10 |
| 2024-03-29 | $49.27M 10-Q · filed 2025-05-13 | $152.31M derived: sum of 2 quarters · filed 2026-02-10 | $158.12M derived: sum of 3 quarters · filed 2026-02-10 | $258.51M derived: sum of 4 quarters · filed 2026-02-10 |
| 2023-12-29 | $103.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $108.86M derived: sum of 2 quarters · filed 2026-02-10 | $209.24M derived: sum of 3 quarters · filed 2026-02-10 | $257.52M 10-K · filed 2026-02-10 |
| 2023-09-29 | $5.82M 10-Q · filed 2024-10-29 | $106.20M derived: sum of 2 quarters · filed 2024-10-29 | $154.48M 10-Q · filed 2024-10-29 | $123.06M derived: sum of 4 quarters · filed 2025-02-11 |
| 2023-06-30 | $100.39M 10-Q · filed 2024-08-06 | $148.66M 10-Q · filed 2024-08-06 | $117.24M derived: sum of 3 quarters · filed 2025-02-11 | $209.28M derived: sum of 4 quarters · filed 2025-02-11 |
| 2023-03-31 | $48.28M 10-Q · filed 2024-04-30 | $16.85M derived: sum of 2 quarters · filed 2025-02-11 | $108.89M derived: sum of 3 quarters · filed 2025-02-11 | $197.40M derived: sum of 4 quarters · filed 2025-02-11 |
| 2022-12-30 | -$31.43M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-11 | $60.62M derived: sum of 2 quarters · filed 2025-02-11 | $149.12M derived: sum of 3 quarters · filed 2025-02-11 | $234.35M 10-K · filed 2025-02-11 |
| 2022-09-30 | $92.04M 10-Q · filed 2023-11-01 | $180.55M derived: sum of 2 quarters · filed 2023-11-01 | $265.78M 10-Q · filed 2023-11-01 | $383.80M derived: sum of 4 quarters · filed 2024-02-06 |
| 2022-07-01 | $88.51M 10-Q · filed 2023-08-01 | $173.74M 10-Q · filed 2023-08-01 | $291.76M derived: sum of 3 quarters · filed 2024-02-06 | $345.02M derived: sum of 4 quarters · filed 2024-02-06 |
| 2022-04-01 | $85.23M 10-Q · filed 2023-05-09 | $203.25M derived: sum of 2 quarters · filed 2024-02-06 | $256.51M derived: sum of 3 quarters · filed 2024-02-06 | $381.40M derived: sum of 4 quarters · filed 2024-02-06 |
| 2021-12-31 | $118.02M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-06 | $171.28M derived: sum of 2 quarters · filed 2024-02-06 | $296.17M derived: sum of 3 quarters · filed 2024-02-06 | $294.15M 10-K · filed 2024-02-06 |
| 2021-10-01 | $53.26M 10-Q · filed 2022-11-01 | $178.15M derived: sum of 2 quarters · filed 2022-11-01 | $176.13M 10-Q · filed 2022-11-01 | $204.26M derived: sum of 4 quarters · filed 2023-02-07 |
| 2021-07-02 | $124.89M 10-Q · filed 2022-08-09 | $122.87M 10-Q · filed 2022-08-09 | $151.00M derived: sum of 3 quarters · filed 2023-02-07 | $112.98M derived: sum of 4 quarters · filed 2023-02-07 |
| 2021-04-02 | -$2.02M 10-Q · filed 2022-05-10 | $26.11M derived: sum of 2 quarters · filed 2023-02-07 | -$11.91M derived: sum of 3 quarters · filed 2023-02-07 | |
| 2021-01-01 | $28.13M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-07 | -$9.89M derived: sum of 2 quarters · filed 2023-02-07 | $130.84M 10-K · filed 2023-02-07 | |
| 2020-10-02 | -$38.02M 10-Q · filed 2021-11-02 | $102.71M 10-Q · filed 2021-11-02 | ||
| 2020-01-03 | $398.11M 10-K · filed 2022-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |